open access

Vol 50, No 2 (2019)
Original Research Article / Praca Oryginalna
Published online: 2019-08-23
Submitted: 2019-02-16
Get Citation

The role of neuronal apoptosis inhibitory protein (NAIP) in acute myeloid leukemia patients

Agnieszka Pluta, Tadeusz Robak, Kamil Brzozowski, Barbara Cebula-Obrzut, Agata Majchrzak, Piotr Pluta, Anna Szmigielska-Kapłon, Olga Grzybowska-Izydorczyk, Magdalena Czemerska, Piotr Stelmach, Piotr Smolewski, Agnieszka Wierzbowska
DOI: 10.2478/ahp-2019-0011
·
Acta Haematol Pol 2019;50(2):74-80.

open access

Vol 50, No 2 (2019)
Original Research Article / Praca Oryginalna
Published online: 2019-08-23
Submitted: 2019-02-16

Abstract

Acute myeloid leukemia (AML) is a heterogeneous, highly malignant neoplasm. Apoptosis is a complex process executed by caspases and suppressed by the inhibitor of apoptosis (IAP) family. Neuronal apoptosis inhibitory protein (NAIP), IAP’s member, may play an exceptional role in the mechanisms of tumors’ resistance to chemotherapy. The aims of the study were to assess the expression of NAIP in leukemic blasts of AML patients using flow cytometry and to evaluate its influence on disease outcome. NAIP expression was found in 106 out of 108 patients. A higher complete response rate was associated with a low expression of NAIP, age < 60 yo, and white blood cell count < 20 G/L ( = 0.009, = 0.033, and = 0.076, respectively) in univariate analyses and a low NAIP expression and age < 60 yo ( = 0.025 and = 0.013, respectively) in multivariate analyses. Longer overall survival (OS) in the univariate analysis was influenced by a low NAIP expression, age < 60 yo, and intensive chemotherapy ( = 0.033, < 0.001, and < 0.001, respectively). In the intensively treated group, better OS was observed in patients with age < 60 yo, AML, and a low NAIP expression ( = 0.03, = 0.024, and = 0.07, respectively). In multivariate analysis, longer OS was associated with age < 60 yo ( = 0.009) and AML ( = 0.007). In conclusion, we suggest that NAIP might play an adverse role in response to chemotherapy.

Abstract

Acute myeloid leukemia (AML) is a heterogeneous, highly malignant neoplasm. Apoptosis is a complex process executed by caspases and suppressed by the inhibitor of apoptosis (IAP) family. Neuronal apoptosis inhibitory protein (NAIP), IAP’s member, may play an exceptional role in the mechanisms of tumors’ resistance to chemotherapy. The aims of the study were to assess the expression of NAIP in leukemic blasts of AML patients using flow cytometry and to evaluate its influence on disease outcome. NAIP expression was found in 106 out of 108 patients. A higher complete response rate was associated with a low expression of NAIP, age < 60 yo, and white blood cell count < 20 G/L ( = 0.009, = 0.033, and = 0.076, respectively) in univariate analyses and a low NAIP expression and age < 60 yo ( = 0.025 and = 0.013, respectively) in multivariate analyses. Longer overall survival (OS) in the univariate analysis was influenced by a low NAIP expression, age < 60 yo, and intensive chemotherapy ( = 0.033, < 0.001, and < 0.001, respectively). In the intensively treated group, better OS was observed in patients with age < 60 yo, AML, and a low NAIP expression ( = 0.03, = 0.024, and = 0.07, respectively). In multivariate analysis, longer OS was associated with age < 60 yo ( = 0.009) and AML ( = 0.007). In conclusion, we suggest that NAIP might play an adverse role in response to chemotherapy.

Get Citation

Keywords

acute myeloid leukemia; apoptosis; NAIP

About this article
Title

The role of neuronal apoptosis inhibitory protein (NAIP) in acute myeloid leukemia patients

Journal

Acta Haematologica Polonica

Issue

Vol 50, No 2 (2019)

Pages

74-80

Published online

2019-08-23

DOI

10.2478/ahp-2019-0011

Bibliographic record

Acta Haematol Pol 2019;50(2):74-80.

Keywords

acute myeloid leukemia
apoptosis
NAIP

Authors

Agnieszka Pluta
Tadeusz Robak
Kamil Brzozowski
Barbara Cebula-Obrzut
Agata Majchrzak
Piotr Pluta
Anna Szmigielska-Kapłon
Olga Grzybowska-Izydorczyk
Magdalena Czemerska
Piotr Stelmach
Piotr Smolewski
Agnieszka Wierzbowska

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl